Onset of action of levetiracetam: a RCT trial using therapeutic intensive seizure analysis (TISA)

Epilepsia
H StefanC Tilz

Abstract

To correlate the onset of clinical effects of add-on levetiracetam (LEV) therapy with daily serum LEV concentration, in pharmaco-resistant focal epilepsies, using the TISA method. 25 adult patients (aged>6 years) with pharmaco-resistant focal epilepsies undergoing presurgical evaluation at the Epilepsy Center Erlangen were enrolled in the study. Eligible patients on a maximum of one other antiepileptic drug (AED) were recruited into the 48-hour baseline phase. Those who had at least two seizures during this phase were randomized into the seven-day treatment phase, when they received either LEV or placebo, under continuous day-and-night video-EEG monitoring. The starting daily dose of LEV was 500 mg bid, titrated from the second treatment day to 1,000 mg bid. The peak serum concentration of LEV was monitored daily at 8:00 am (one hour after drug administration) for every patient. The number and duration of seizures per 24h (N/24h and D/24h respectively) were investigated. 23 patients completed the study (LEV group n=11 and placebo group n=12). Seven patients in the LEV group and two patients in the placebo group achieved seizure-freedom during the treatment phase. The intergroup comparison of the decrease in N/24h and D/24h from...Continue Reading

References

Nov 10, 1992·European Journal of Pharmacology·A J GowerE Wülfert
Jan 1, 1989·Psychopharmacology·D E Casey
Jul 1, 1981·Neurology·T L RileyJ K Penry
Nov 24, 1999·Neurology·S LaowattanaD Ashmead
Mar 18, 2000·Pharmacology & Therapeutics·P N Patsalos
Sep 6, 2000·Brain, Behavior and Evolution·T H Bullock
Oct 9, 2001·Acta Neurologica Scandinavica·H StefanE Pauli
Oct 8, 2003·European Journal of Clinical Pharmacology·Margherita Strolin BenedettiEugène Baltes
Jun 24, 2004·Proceedings of the National Academy of Sciences of the United States of America·Berkley A LynchBruno Fuks
Jul 17, 2004·Therapeutic Drug Monitoring·Manuela ContinAgostino Baruzzi
Jul 20, 2004·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·H StefanB Schmidt
Aug 3, 2004·Acta Neurologica Scandinavica·G CapovillaD Paganelli
Aug 11, 2004·Clinical Pharmacokinetics·Philip N Patsalos
Aug 25, 2004·Seizure : the Journal of the British Epilepsy Association·S Pradeep Kumar, Philip E M Smith
Sep 1, 2004·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Suzanne Weber, Roy G Beran
Feb 1, 2005·Epilepsia·Jacqueline French, Celestina Arrigo

❮ Previous
Next ❯

Citations

Jan 9, 2008·Neurocritical Care·Nicholas S AbendDennis J Dlugos
May 8, 2009·Epilepsy Currents·Bassel W Abou-Khalil
Sep 26, 2012·Evidence-based Complementary and Alternative Medicine : ECAM·Yan WangGuo-Qing Zheng
Oct 3, 2008·Neuropsychiatric Disease and Treatment·Bassel Abou-Khalil
Jun 10, 2011·Journal of Neurophysiology·Anna L MeehanSteven M Rothman
May 29, 2007·Therapeutic Drug Monitoring·Oriano MecarelliNicola Vanacore
Apr 3, 2010·Brain & Development·Jiahui LiSiyuan Chen
Mar 20, 2009·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·H Stefan, R Hopfengärtner
Feb 21, 2008·Epilepsy & Behavior : E&B·R KuznieckyH Hetherington
Feb 23, 2018·Annals of Clinical and Translational Neurology·Daniel M GoldenholzWilliam H Theodore
Nov 17, 2020·Seizure : the Journal of the British Epilepsy Association·Valerija LamouretBernhard J Steinhoff

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.